Respien

Respien is an Australian clinical-stage biopharmaceutical company focused on developing novel immunotherapies for chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis (NCFB). The company's lead asset, HI-164, is a Phase 3-ready oral biologic (a whole-cell killed bacterial vaccine targeting non-typeable Haemophilus influenzae) designed to prevent recurrent bacterial exacerbations and reduce hospital admissions. In Phase 2 clinical trials involving over 500 patients, HI-164 demonstrated a 50–73% reduction in hospital admissions and significant improvements in patient quality of life. Respien's pipeline also includes TA-270, an inhaled or oral small molecule that acts as a dual 5-lipoxygenase (5-LOX) inhibitor and peroxynitrite scavenger to reduce inflammation and oxidative stress in the lungs. The company is actively seeking global or regional partners to advance its late-stage respiratory programs into Phase 3 development and commercialization.